Bruker (NASDAQ:BRKR) Sets New 52-Week High – What’s Next?

Bruker Corporation (NASDAQ:BRKR)’s share price hit a new 52-week high on Friday . The stock traded as high as $65.30 and last traded at $63.6650, with a volume of 79419 shares trading hands. The stock had previously closed at $64.34.

Analyst Ratings Changes

Several analysts have issued reports on BRKR shares. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. TD Cowen reissued a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Guggenheim increased their target price on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Citigroup raised their price target on shares of Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $56.79.

Bruker Stock Down 4.2%

The firm has a market cap of $9.39 billion, a price-to-earnings ratio of -255.65, a price-to-earnings-growth ratio of 1.98 and a beta of 1.29. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average of $57.81 and a 200-day moving average of $46.54.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same period in the prior year, the business earned $0.47 EPS. The firm’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio is currently -83.33%.

Institutional Trading of Bruker

Several hedge funds have recently bought and sold shares of the company. Los Angeles Capital Management LLC bought a new position in Bruker in the 4th quarter worth about $26,000. Allworth Financial LP grew its holdings in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares in the last quarter. Essential Partners LLC acquired a new stake in Bruker in the 1st quarter valued at approximately $36,000. Parallel Advisors LLC raised its stake in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in Bruker during the 4th quarter worth $50,000. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.